NCT03886766View on ClinicalTrials.gov

Bioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid Dispersions

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

March 19, 2020

Study Completion Date

March 19, 2020

Conditions
Biological AvailabilityAmorphous Solid Dispersions
Interventions
DRUG

Hot-melt extruded amorphous solid dispersion of Efavirenz

Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)

DRUG

Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles

Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)

DRUG

Efavirenz solution

Efavirenz solution, 3 mg, oral administration (product 3)

Trial Locations (1)

4056

Pharmaceutical Technology, University of Basel, Pharmazentrum, Basel

All Listed Sponsors
collaborator

University of Basel

OTHER

lead

University Hospital, Basel, Switzerland

OTHER

NCT03886766 - Bioavailability Mechanistic Study of Hot-Melt Extruded Amorphous Solid Dispersions | Biotech Hunter | Biotech Hunter